Kite Pharma, Inc. (NASDAQ:KITE) Files An 8-K Other Events
Item8.01
| Other Events. |
On March2, 2017, Kite Pharma, Inc. (Kite) entered into an
Underwriting Agreement (the Underwriting Agreement) with
Jefferies LLC, as the representative of the several underwriters
(the Underwriters), relating to the offering, issuance and sale
(the Offering) of 4,750,000 shares of Kites common stock, $0.001
par value per share (the Common Stock), at a price to the public
of $75.00 per share, which Kite estimates will result in
approximately $347.4million of net proceeds to Kite after
deducting the underwriting discounts and commissions and
estimated offering expenses. The Offering is expected to close on
or about March7, 2017, subject to customary closing conditions.
In addition, the Underwriters have a 30-day option to purchase up
to an additional 712,500 shares of Common Stock. All of the
shares in the Offering are being sold by Kite.
The Offering is
being made to Kites effective shelf registration statement on
Form S-3ASR (Registration No.333-208382) previously filed with
the Securities and Exchange Commission. The Offering is being
made only by means of a prospectus supplement and an accompanying
prospectus.
The Underwriting
Agreement contains customary representations, warranties and
agreements by Kite, conditions to closing, indemnification
obligations of Kite and the Underwriters, including for
liabilities under the Securities Act of 1933, as amended, other
obligations of the parties and termination provisions. The
representations, warranties and covenants contained in the
Underwriting Agreement were made only for purposes of such
agreement and as of specific dates, were solely for the benefit
of the parties to such agreement and may be subject to
limitations agreed upon by the contracting parties.
The Underwriting
Agreement is filed as Exhibit 1.1 hereto and is incorporated
herein by reference. The foregoing description of the terms of
the Underwriting Agreement is qualified in its entirety by
reference to such exhibit. A copy of the opinion of Cooley LLP
relating to the legality of the issuance and sale of the shares
in the Offering is attached as Exhibit 5.1 hereto.
| Item9.01 | Financial Statements and Exhibits. |
(d)
Exhibits.
The following
exhibits are filed as part of this Current Report:
| 1.1 |
Underwriting Agreement, dated March2, 2017, by and between Kite Pharma, Inc. and Jefferies LLC, as the representative of the several underwriters. |
|
| 5.1 | Opinion of Cooley LLP. | |
| 23.1 | Consent of Cooley LLP (included in Exhibit 5.1). |
About Kite Pharma, Inc. (NASDAQ:KITE)
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL. Kite Pharma, Inc. (NASDAQ:KITE) Recent Trading Information
Kite Pharma, Inc. (NASDAQ:KITE) closed its last trading session up +1.37 at 73.90 with 2,101,950 shares trading hands.
